Comparative in vitro activity of meropenem versus other extended- spectrum antimicrobials against randomly chosen and selected resistant clinical isolates tested in 26 North American centers

Clinical Infectious Diseases

Volumn 24, Issue SUPPL. 2, 1997, Pages

  Pitkin, Donald H ^a   Sheikh, Waheed ^b   Nadler, Harriette L ^b  

^a Zeneca Pharmaceutical B   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CLINDAMYCIN; GENTAMICIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; PIPERACILLIN; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL;

EID: 0030947003     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.supplement_2.s238     Document Type: Article

References (4)

1. Bauernfeind A, Jungwirth R, Schweighart S. In-vitro activity of meropenem, imipenem, and penem HRE 664 and ceftazidime against clinical isolates from West Germany. J Antimicrob Chemother 1989;24(suppl A):73-84.
2. Edwards JR, Turner PJ, Wannop C, Withnell ES, Grindey AJ, Nairn K. In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with stability to dehydropeptidase I. Antimicrob Agents Chemother 1989; 33:215-22.
3. Nord CE, Lindmark A, Persson I. Susceptibility of anaerobic bacteria to SM-7338 [abstract no 596]. In: Program and abstracts of the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1988:213.
4. Okuda T, Fukasawa M, Tanio T, Sumita Y, Tada E, Yukimatsu T. SM-7338, a new carbapenem antibiotic: in vitro and in vivo antibacterial activities [abstract no 757], In: Program and abstracts of the 27th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1987:229.